<DOC>
	<DOCNO>NCT01975246</DOCNO>
	<brief_summary>This multi-centre , randomised , double-blind , active-controlled , parallel-group comparative trial compare fix dose combination ( FDC ) telmisartan 80 mg +hydrochlorothiazide 12.5 mg amlodipine 5 mg ( T80/A5/H12.5 mg ) telmisartan 80 mg+ amlodipine 5 mg ( T80/A5 mg ) blood pressure lower effect week 8 , end double-blind period essential hypertensive patient fail respond adequately telmisartan 80 mg+ amlodipine 5 mg . Patients assign one two group 6-week open-label run-in period take T80/A5 mg .</brief_summary>
	<brief_title>Add-on Micamlo BP Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : Essential hypertensive patient already take 2 3 antihypertensive drug mean seat diastolic blood pressure ( DBP ) must &gt; =90 &lt; =114 mmHg mean seat systolic blood pressure ( SBP ) must = &lt; 200 mmHg Able stop current antihypertensive drug ( study medication ) Visit 1b end trial without risk patient base investigator 's opinion Age 20 year old Exclusion criterion : Patients know suspected secondary hypertension Patients clinically relevant cardiac arrhythmia Congestive heart failure New York Heart Association ( NYHA ) functional class IIIIV Patients recent cardiovascular event Patients recent stroke event Patients history sudden deterioration renal function angiotensin II receptor blocker angiotensin convert enzyme inhibitor ; patient postrenal transplant postnephrectomy Patients hepatic and/or renal dysfunction Premenopausal woman nurse pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>